NCT04558931 - Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2032

Conditions

Multiple Myeloma

Interventions

DRUG

CellProtect

In vitro expanded and activated autologous NK cells

DRUG

Isatuximab

Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38

Trial Locations (1)

17177

RECRUITING

Karolinska University Hospital, Huddinge, Stockholm